生物活性小化合物有效抑制ChREBP过度表达以治疗NAFLD和T2DM:一种计算药物开发方法
Hiron Saraj Devnath1, Maisha Maliha Medha1, Md Naharul Islam1
1Pharmacy Discipline, Khulna University, Khulna, 9208, Bangladesh.
Heliyon
|March 4, 2025
概括
研究人员确定了针对碳水化合物反应元素结合蛋白 (ChREBP) 的天然化合物,用于治疗非酒精性脂肪肝疾病 (NAFLD) 和II型糖尿病 (T2DM). 五种植物化学物质显示出作为有效药物候选物的强大潜力.
科学领域:
- 生物化学和分子生物学
- 药理学和药物发现
- 代谢疾病 代谢疾病
背景情况:
- 碳水化合物反应元素结合蛋白 (ChREBP) 是葡萄糖代谢的关键调节者,与NAFLD和T2DM有关.
- 向ChREBP为这些普遍的代谢障碍提供了潜在的治疗策略.
研究的目的:
- 为了确定新型的天然小分子作为潜在的药物候选者,抑制ChREBP活性.
- 评估这些化合物的治疗NAFLD和T2DM的疗效和安全性.
主要方法:
- 利用一种in silico药物设计策略,包括对抗ChREBP的分子对接.
- 选了494种植物化学物质和20种FDA批准的抗糖尿病药物.
- 评估ADMET特性,并对顶级候选者进行分子动力学模拟.
主要成果:
- 确定了五种天然化合物 (dieckol,isocorilagin,stachyurin,stachysetin, thonningianin A),它们与ChREBP.有良好的结合亲和关系.
- 这些化合物通过MD模拟证明了良好的ADMET配置文件和稳定性.
- 选择的植物化学物质显示出作为治疗剂的巨大潜力.
结论:
- 迪科尔 (Dieckol),异基拉丁 (isocorilagin),稳尿素 (stachyurin),稳素 (stachysetin) 和宁氨酸A是对NAFLD和T2DM有前途的候选药物.
- 在 silico 查和验证为进一步的临床前发展提供了坚实的基础.
- 用天然化合物准ChREBP是一个可行的治疗途径.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
506
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
506
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Drug Discovery: Overview
7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
Structure-Activity Relationships and Drug Design
480
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
480
Glucagon-like Receptor Agonists
290
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
290
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K


